Losartan Side Effects: Incidence Rates Across Clinical Trials

Overview of Losartan's Adverse Event Profile

Losartan (brand name Cozaar) was the first oral angiotensin II receptor blocker approved by the FDA in 1995, and decades of trial data have produced a detailed picture of its tolerability. The drug blocks AT1 receptors without inhibiting ACE, which is why it produces far less bradykinin accumulation and therefore far less cough than ACE inhibitors. FDA prescribing information lists dizziness, upper respiratory infection, and fatigue as the most frequently reported adverse events in controlled hypertension trials.

How Trial-Derived Rates Differ from Real-World Rates

Trial populations are selected. Patients with severe renal impairment, uncontrolled diabetes at enrollment, and certain concomitant medications are often excluded, which tends to understate the rates seen in general clinical practice. Post-market surveillance captured through the FDA Adverse Event Reporting System (FAERS) consistently records higher proportional reporting ratios for hyperkalemia and renal adverse events than the key trial labels suggest. FAERS data should be interpreted as signal-generating rather than incidence-confirming, but the direction of the signal matters clinically.

Dose-Dependent Considerations

The approved dose range is 25 mg to 100 mg daily. At 50 mg (the most common starting dose), the side effect burden in controlled trials was low. Titrating to 100 mg increased antihypertensive efficacy in RENAAL but also increased the frequency of renal and electrolyte adverse events. Clinicians should recheck serum potassium and creatinine within two to four weeks of any dose escalation.

Adverse Events in the LIFE Trial

The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) trial enrolled 9,193 patients with hypertension and electrocardiographic evidence of left ventricular hypertrophy. Participants were randomized to losartan 50 to 100 mg or atenolol 50 to 100 mg. The primary outcome was the composite of cardiovascular death, stroke, or myocardial infarction. Dahlöf et al. Published the results in The Lancet in 2002, showing a 13% relative risk reduction (RRR) favoring losartan (P=0.021).

Tolerability Data from LIFE

Withdrawal due to adverse events was 9.5% in the losartan arm versus 14.9% in the atenolol arm. Dizziness was reported in 3.5% of losartan patients. New-onset diabetes occurred in 6.0% of the losartan group versus 8.1% in the atenolol group, a finding that reflected a metabolic benefit rather than a harm. Cough (the signature ACE inhibitor side effect) was not elevated above background rates in the losartan arm.

Hyperkalemia was not reported as a significant adverse event in LIFE because the trial excluded patients with baseline potassium above 5.0 mEq/L and those with serum creatinine above 1.7 mg/dL in women or 2.0 mg/dL in men. That exclusion criterion is clinically important: the LIFE tolerability data cannot be extrapolated to patients with chronic kidney disease (CKD) stage 3b or higher.

Stroke Subgroup and Safety in High-Risk Patients

A prespecified subgroup analysis in patients with isolated systolic hypertension showed no increased adverse event rate with losartan. Among patients with prior stroke, the composite event rate favored losartan, and adverse event-driven discontinuation remained lower than in the atenolol group. The pattern suggests that tolerability advantages persist in secondary-prevention settings.

Adverse Events in the RENAAL Trial

RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) enrolled 1,513 patients with type 2 diabetes and nephropathy (defined by proteinuria and serum creatinine 1.3 to 3.0 mg/dL). Patients received losartan 50 to 100 mg or placebo on top of conventional antihypertensive therapy. Brenner et al. Published RENAAL in the New England Journal of Medicine in 2001.

Key RENAAL Adverse Event Rates

| Adverse Event | Losartan (%) | Placebo (%) | |---|---|---| | Hyperkalemia | 3.3 | 0.9 | | Elevated creatinine | 9.9 | 3.7 | | Hypotension | 14.1 | 10.3 | | Diarrhea | 14.5 | 13.2 | | Anemia | 12.4 | 10.0 | | Dizziness | 4.0 | 2.8 |

Source: RENAAL trial safety appendix, NEJM 2001 [1].

Hyperkalemia and creatinine elevation in RENAAL were managed with dose adjustment and dietary modification in most cases; only a small fraction of patients required drug discontinuation for these findings. The 9.9% rate of elevated creatinine reflects the population (baseline eGFR was often below 40 mL/min/1.73 m²) as much as the drug itself. An initial modest rise in creatinine after starting an ARB is expected due to efferent arteriolar dilation, and a rise of up to 30% above baseline that stabilizes within two months is generally considered acceptable rather than harmful. Current guidelines from the American Diabetes Association support continued ARB use in diabetic nephropathy despite initial creatinine rises within this range.

Managing Hyperkalemia in RENAAL-Like Patients

A serum potassium above 5.5 mEq/L warrants dose reduction or temporary discontinuation. Dietary potassium restriction (targeting below 3,000 mg/day in advanced CKD) and co-administration of sodium bicarbonate to correct metabolic acidosis can help maintain potassium within an acceptable range while keeping the patient on renal-protective therapy. The potassium-binding agent patiromer was not available during RENAAL but has since been shown in the AMBER trial (N=295) to allow continuation of spironolactone and ARB therapy in patients with resistant hypertension and CKD, achieving potassium control in 66% of patients versus 43% with placebo. See the AMBER results on PubMed.

Adverse Events in the ELITE II Trial

The ELITE II trial compared losartan 50 mg with captopril 50 mg three times daily in 3,152 elderly patients with heart failure (NYHA class II, IV, LVEF ≤40%). Pitt et al. Published ELITE II in The Lancet in 2000. The primary hypothesis was that losartan would reduce all-cause mortality more than captopril. That hypothesis was not confirmed (all-cause mortality 11.7% losartan vs 10.4% captopril; P=0.16), but the trial produced valuable comparative tolerability data.

Tolerability Advantage Over ACE Inhibitors

Losartan was significantly better tolerated. Drug-related adverse events occurred in 30% of the losartan group versus 40.8% in the captopril group (P<0.001). Cough causing withdrawal was 0.3% with losartan versus 2.7% with captopril. Any cough (not just discontinuation-causing) was reported in 17.5% of captopril patients versus 8.8% on losartan. Taste disturbance and rash, both more common with ACE inhibitors due to bradykinin accumulation, were also less frequent on losartan.

The practical implication: for ACE inhibitor-intolerant patients, especially those with persistent cough or angioedema not linked to a kinin mechanism, losartan is a reasonable alternative. Prescribers should note, however, that cross-reactive angioedema to ARBs has been reported in patients with ACE inhibitor-induced angioedema, with an estimated incidence between 2% and 17% depending on the case series consulted. A review in the Annals of Internal Medicine estimated the risk of ARB-related angioedema in ACE inhibitor-sensitized patients at approximately 9.4%.

Rare but Serious Adverse Events

Angioedema

The FDA label for losartan includes a warning for angioedema, reported in <1% of patients in controlled trials. The mechanism differs from ACE inhibitor angioedema in that bradykinin does not accumulate with ARBs. Instead, angiotensin II itself may have a minor role in angioedema via AT2 receptor stimulation. Cases have occurred in the absence of any prior ACE inhibitor use. Any patient who develops oropharyngeal or laryngeal swelling should discontinue losartan immediately, and re-challenge is contraindicated.

Rhabdomyolysis

Rhabdomyolysis with losartan is rare, documented primarily through FAERS case reports rather than trial data. A pharmacovigilance analysis published in PLOS ONE found that ARBs as a class have a lower proportional reporting ratio for rhabdomyolysis than many other antihypertensives, but individual cases exist. The mechanism may involve drug-drug interactions (most commonly with statins, where losartan inhibits CYP2C9 and can raise statin exposure by a modest amount).

Fetal Toxicity

Losartan carries an FDA Black Box Warning for fetal toxicity. Use during the second and third trimesters causes fetal renal dysplasia, oligohydramnios, skeletal malformations, and neonatal renal failure. The FDA mandates that prescribers counsel patients of reproductive potential at every visit. Discontinuation should occur as soon as pregnancy is confirmed. The full Black Box Warning text is in the FDA-approved label.

Hepatotoxicity

Rare cases of losartan-associated hepatocellular injury have appeared in the literature. The LiverTox database maintained by the NIH classifies losartan as a rare cause of clinically apparent liver injury, with a latency of one to eight weeks and a mixed hepatocellular-cholestatic pattern on liver biopsy in documented cases. Routine LFT monitoring is not mandated in the label but may be prudent in patients with pre-existing hepatic disease, where the drug's active metabolite EXP3174 may accumulate at higher-than-expected plasma concentrations.

Electrolyte and Renal Adverse Events: A Deeper Look

Hyperkalemia and creatinine elevation are the two most clinically managed adverse events with losartan. Both reflect the drug's mechanism rather than off-target toxicity.

Hyperkalemia Risk Stratification

Baseline features that predict hyperkalemia on ARB therapy include eGFR <45 mL/min/1.73 m², baseline potassium above 4.5 mEq/L, concurrent use of potassium-sparing diuretics or NSAIDs, and type 2 diabetes with hyporeninemic hypoaldosteronism. A prediction model published in the British Medical Journal in 2015 (N=30,735) identified these variables as independently associated with ARB-related hyperkalemia with a C-statistic of 0.79.

For patients at high risk, checking serum electrolytes and creatinine at one week and four weeks after starting or up-titrating losartan is a practical monitoring interval. The 2021 ESC Guidelines on Cardiovascular Disease Prevention recommend monitoring renal function within one to two weeks of initiation or dose change.

When to Stop vs. Adjust

A serum potassium of 5.0 to 5.5 mEq/L calls for dietary review and recheck within one to two weeks. A value of 5.5 to 6.0 mEq/L calls for dose halving, a dietitian referral, and recheck within one week. A value above 6.0 mEq/L or any ECG change associated with hyperkalemia warrants same-day discontinuation and urgent evaluation.

The above tiered response framework is based on expert consensus guidance from the American Society of Nephrology's chronic kidney disease management recommendations and the RENAAL safety protocol, adapted by the HealthRX clinical team for outpatient telehealth practice. It is intended for use alongside, not instead of, direct physician assessment.

Cough and Respiratory Adverse Events

One of the most-cited clinical advantages of ARBs over ACE inhibitors is a substantially lower rate of dry cough. A 2012 meta-analysis in the Annals of Internal Medicine of 72 randomized trials (N=58,492) found that ARBs produced cough in approximately 3.2% of patients versus 11.5% for ACE inhibitors (relative risk 0.28, 95% CI 0.22 to 0.35). Losartan-specific rates in ELITE II (8.8%) were higher than this pooled average, likely because some ELITE II patients had previously used ACE inhibitors and retained heightened cough sensitivity.

Upper respiratory infection (URI) was reported in 8% of losartan patients versus 7% of placebo patients in the controlled hypertension trials listed in the package insert. This small absolute difference is not considered drug-related; losartan does not impair immune function.

Cardiovascular Adverse Events Across Trials

Losartan does not cause meaningful direct cardiotoxicity. In LIFE, fatal and non-fatal myocardial infarction rates were similar between losartan and atenolol (4.5% vs 4.9%), with no excess attributable to losartan. Hypotension was dose-dependent and occurred in 3 to 7% of patients in hypertension trials; this rate rose to 14.1% in RENAAL's CKD population.

A meta-analysis published in The Lancet in 2010 (N=146,838 across 26 trials of RAAS inhibitors) confirmed that ARBs, including losartan, do not increase myocardial infarction risk, directly addressing the controversy raised by earlier observational analyses.

Atrial Fibrillation

The LIFE trial prespecified atrial fibrillation (AF) as a secondary endpoint. New-onset AF occurred in 6.8 per 1,000 patient-years in the losartan arm versus 10.1 per 1,000 patient-years in the atenolol arm (relative risk reduction 33%, P=0.0001). This AF-prevention signal has not translated into an FDA-approved indication for AF prevention, but it is clinically relevant when choosing among antihypertensives in patients with AF risk factors. The AF sub-analysis from LIFE is available on PubMed.

Drug Interactions That Modify the Adverse Event Profile

Losartan is metabolized to its active carboxylic acid metabolite EXP3174 via CYP2C9, with a minor contribution from CYP3A4. Drugs that inhibit CYP2C9 (fluconazole, amiodarone, certain NSAIDs) can increase EXP3174 plasma concentrations and magnify blood-pressure-lowering and potassium-elevating effects.

NSAIDs present a two-directional interaction risk. They blunt the antihypertensive efficacy of losartan by blocking prostaglandin-mediated renal vasodilation, and they independently raise potassium by inhibiting aldosterone. Combined use in elderly patients or those with CKD generates the "triple whammy" (ARB plus NSAID plus diuretic) pattern that multiple observational studies have linked to acute kidney injury. A BMJ study of 487,372 patients found that the combination tripled the 30-day risk of acute kidney injury versus any single agent alone.

Rifampicin, a potent CYP2C9 inducer, reduces EXP3174 exposure by approximately 30%, potentially reducing antihypertensive efficacy. Losartan dose may need upward adjustment in patients on rifampicin-based tuberculosis regimens.

FAERS Post-Market Data

The FDA's FAERS database through Q3 2024 contains over 28,000 reports mentioning losartan as a suspect drug. The top five preferred terms by report count are: hypotension (4,112 reports), renal impairment (3,847 reports), dizziness (3,201 reports), hyperkalemia (2,988 reports), and fall (2,103 reports). Reporting rates in FAERS are not incidence rates. They reflect spontaneous reporting biases, label updates that stimulate reporting, and media attention cycles.

Disproportionality analyses using the reporting odds ratio (ROR) have identified statistically elevated signals for losartan and: acute kidney injury (ROR 4.2, 95% CI 3.9 to 4.6), hyperkalemia (ROR 3.8), and rhabdomyolysis (ROR 1.9). These signals are consistent with the known pharmacology and should prompt heightened monitoring but do not indicate that losartan causes these events at rates above those seen in clinical trials in appropriately selected patients.

The FAERS public dashboard allows clinicians and patients to search individual drug reports directly.

Adherence and Tolerability in Real-World Practice

A retrospective cohort study using the UK Clinical Practice Research Datalink (CPRD), published in PLOS ONE, evaluated one-year persistence with ARBs versus ACE inhibitors in 120,173 newly treated hypertensive patients. ARB users had 12% higher one-year persistence compared with ACE inhibitor users, driven almost entirely by lower cough and angioedema-related discontinuations.

Within the ARB class, losartan's once-daily dosing, generic availability, and low pill burden support adherence. Approximately 67% of patients in community pharmacy studies remain on their originally prescribed ARB at 12 months, compared with 58% for ACE inhibitors. The one-year discontinuation rate for losartan specifically in the Clinical Practice Research Datalink cohort was 28%, with adverse events accounting for only 6% of discontinuations; cost and physician switching explained the rest.